Adherence to interferon-beta treatment and results of therapy switching

Journal of the Neurological Sciences

Volumn 259, Issue 1-2, 2007, Pages 104-108

  Clerico, Marinella ^a   Barbero, Pierangelo ^a   Contessa, Giulia ^a   Ferrero, Cinzia ^a   Durelli, Luca ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Interferon dose reduction; Interferon treatment; Multiple sclerosis; Treatment compliance; Treatment response indicators

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEPRESSION; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; IMMUNOMODULATION; INJECTION SITE REACTION; LIVER FUNCTION TEST; LONG TERM CARE; LOW DRUG DOSE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADJUVANTS, IMMUNOLOGIC; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 34447097239     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.05.075     Document Type: Article

References (23)

1. Ruggieri M.N., Settipani N., Viviano L., Attanasio M., Giglia L., Almasio P., Giglia L., et al. Long term interferon-β treatment for multiple sclerosis. Neurol Sci 24 (2003) 361-364
2. Haas J., and Firzlaff M. Twenty-four-months comparison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®). Eur J Neurol 12 (2005) 425-431
3. Milanese L., La Mantia L., Palumbo R., Martinelli V., Murialdo A., Zaffaroni M., et al. A post-marketing study on interferon β-1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 74 (2003) 1689-1692
4. Goodin D.S., Frohman E.M., Garmany G.P., et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58 (2002) 169-178
5. Tremlett H.L., and Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 61 4 (2003) 551-554
6. Rio J., Porcel J., Tellez N., Sanchez-Betancourt A., Tintore M., Arevalo M.J., et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 11 3 (2005) 306-309
7. O'Rourke K.E., and Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 11 1 (2005) 46-50
8. Mohr D.C., Goodkin D.E., Likosky W., Gatto N., Neilley L.K., Griffin C., et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 2 (1996) 222-226
9. Barbero P., Verdun E., Bergui M., Pipieri A., Clerico M., Cucci A., et al. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study. J Neurol Sci 222 1-2 (2004) 13-19
10. Kracke A., von Wussow P., Al-Masri A.N., Dalley G., Windhagen A., and Heidenreich F. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 54 (2000) 193-199
11. Pachner A.R., Narayan K., and Park E. Multiplex analysis of expression of three IFNβ induced genes in antibody-positive MS patients. Neurology 66 (2006) 444-446
12. Pachner A.R., Bertolotto A., and Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNβ bioactivity. Detection of antibody-mediated decreased bioactivity (ADB). Neurology 61 Suppl 5 (2003) S24-S26
13. Bertolotto A., Sala A., Malucchi S., Marnetto F., Caldano M., Di Sapio A., et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry 75 (2004) 1294-1299
14. Killestein J., Hintzen R.Q., Uitdehaag B.M., Baars B.A., Roos M.T., van Lier R.A., et al. Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta. J Neuroimmunol 133 (2002) 217-224
15. Petereit H.F., Nolden S., Schoppe S., Bamborschke S., Pukrop R., and Heiss W.D. Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients. Mult Scler 8 (2002) 492-494
16. Wandinger K.P., Lunemann J.D., Wengert O., Bellman Strobl J., Aktas O., Weber A., et al. TNF-related apoptosis inducing ligand (TRIAL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 361 (2003) 2036-2043
17. Batocchi A.P., Rotondi M., Caggiula M., Frisullo G., Odoardi F., Nociti V., et al. Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. J Neuroimmunol 139 (2003) 150-154
18. Laske C., Oschmann P., Tofighi J., Kuhne B.S., Diehl H., Branzerger T., et al. Prognostic value of soluble tumor necrosis factor receptor 1 and 2 in multiple sclerosis patients treated with interferon-beta 1b. Eur Neurol 46 4 (2001) 210-214
19. Cook S.D., Quinless J.R., Jotkowitz A., and Beaton P. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology 57 (2001) 1080-1084
20. Rudick R.A., Simonian N.A., Alam J.A., Campion M., Scaramucci J.O., Jones W., et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50 5 (1998) 1266-1272
21. Durelli L., Oggero A., Verdun E., Barbero P., Pipieri A., Isoardo G., et al. Interferon-beta dose and efficacy: the OPTIMS study. Neurol Sci 22 2 (2001) 201-203
22. Durelli L., Verdun E., Barbero P., Bergui M., Pipieri A., Ricci A., et al. The optimization of interferon for MS (OPTIMS) study. A multicenter trial comparing two different doses of IFN beta-1b. Neurology 62 Suppl 2 (2004) A153 [Abstract]
23. Río J., Nos C., Tintoré M., Téllez N., Galán I., Pelayo R., et al. Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients. Ann Neurol 59 (2006) 344-352